RE:RE:RE:RE:RE:RE:Short interest on THTX plummetsNo oncology data until next year???? I am not sure why you think that. The trial is to start in the second quarter and since it is open label, we can expect to hear about any good news close to when the company discovers it. So, there shoould be quite a lot of important, likely market moving, cancer news this year. Moreover, I suspect the larger institutions in the deal were likely in it more for cancer than for NASH. We also should be hearing something important from the AACR conference on cancer in early April. On NASH, the news has been announced that they are a phase III player but the stock has not discounted that yet and so investors are getting NASH for free, something that is not true for any other NASH stock. While the company has been boneheaded about addressing that huge valuation gap so far, it sounds like they may finally be waking up. So, 2021 could be a banner year for TH's stock as some of the past unjustices and the impact of the idiotic share offering pass.
jeffm34 wrote: you do if you think there is nothing to move the share price in the short or medium term. All we have for the rest of 2021 is product sales to go on. Oncology data won't start coming out until next year. The confirmation of an already announced phase 3 NASH trial isn't going to move anything
SPCEO1 wrote: Some certainly are going to do that, or already have done that, but I really don't think all 16.7 million new shares are likely to be sellers as soon as the stock hits $2.75 (or $2.50 depending on how or if you want to incorporate a value for the warrants).
jeffm34 wrote: It's a free ride with the warrants. Sell the shares as soon as they are profitable and you still have lots of risk free upside with the warrants.